Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167000 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL14934059 | 0.85 | MEN1 (0.41) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL115650 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL23455648 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL15714285 | 0.81 | KIF11 (0.50) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL19661475 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL112521 | 0.79 | LMNA (0.56) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL9226616 | 0.78 | TAS2R14 (0.50) | MEN1KMT2AGAAMAPTRAB9A | |
| SCHEMBL9285908 | 0.78 | CES2 (0.46) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL9226482 | 0.78 | MEN1 (0.47) | MEN1KMT2AKIF11HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| CN-115768761-A | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| EP-4129406-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022133098-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| EP-2424856-B1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| WO-2012057273-A1 | HARMFUL ANIMAL CONTROL COMPOSITION AND METHOD FOR CONTROLLING HARMFUL ANIMALS | 住友化学株式会社 (JP) | 2012-05-03 | — | — | WO | disclosed |
| CN-102414195-A | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL CO | 2012-04-11 | — | — | CN | disclosed |
| EP-2424856-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009217-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| CN-101155787-B | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| WO-2010125985-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125985-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | WO | disclosed |
| CN-101155787-A | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | ALDH1A1 3333/4885MEN1 725/4885KMT2A 4282/4885 |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | ALDH1A1 3522/4885MEN1 297/4885KMT2A 428/4885 |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | ALDH1A1 2046/4885MEN1 859/4885KMT2A 3130/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | ALDH1A1 1409/4885MEN1 637/4885KMT2A 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.